US2019201391A1PendingUtilityA1

Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders

73
Assignee: AVANIR PHARMACEUTICALS INCPriority: Jul 17, 2002Filed: Jul 26, 2018Published: Jul 4, 2019
Est. expiryJul 17, 2022(expired)· nominal 20-yr term from priority
A61K 31/49A61P 25/02A61K 31/4748A61K 31/485A61K 31/4709A61K 45/06A61K 2300/00
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.

Claims

exact text as granted — not AI-modified
1 . A method for treating traumatic brain injury, the method comprising administering to a patient in need thereof dextromethorphan in combination with quinidine, wherein the amount of dextromethorphan administered comprises from about 20 mg/day to about 60 mg/day and wherein the amount of quinidine administered comprises from about 10 mg/day to about 30 mg/day with the proviso that the weight-to-weight ratio of dextromethorphan to quinidine is 1:0.75 or less of quinidine. 
     
     
         2 . The method of  claim 1 , wherein the dextromethorphan and the quinidine are administered as one combined dose per day. 
     
     
         3 . The method of  claim 1 , wherein the dextromethorphan and the quinidine are administered as at least two combined doses per day. 
     
     
         4 . The method of  claim 1 , wherein the amount of quinidine administered comprises from about 20 mg/day to 30 mg/day. 
     
     
         5 . The method of  claim 1 , wherein the amount of dextromethorphan administered comprises from about 40 mg/day to 60 mg/day. 
     
     
         6 . The method of  claim 1 , wherein at least one of the quinidine and the dextromethorphan is in a form of a pharmaceutically acceptable salt. 
     
     
         7 . The method of  claim 1 , wherein at least one of the quinidine and the dextromethorphan is in a form of a pharmaceutically acceptable salt selected from the group consisting of salts of free acids, inorganic salts, salts of sulfate, salts of hydrochloride, and salts of hydrobromide. 
     
     
         8 . The method of  claim 1 , wherein about 20 mg quinidine sulfate is administered per day. 
     
     
         9 . The method of  claim 1 , wherein about 60 mg dextromethorphan hydrobromide is administered per day. 
     
     
         10 . The method of  claim 1  wherein the dextromethorphan and quinidine are administered in separate doses. 
     
     
         11 . The method of  claim 1  wherein the weight-to-weight ratio of dextromethorphan to quinidine is 1:0.65 or less of quinidine. 
     
     
         12 . The method of  claim 1 , wherein about 40 mg dextromethorphan hydrobromide is administered per day. 
     
     
         13 . The method of  claim 1 , wherein about 60 mg of dextromethorphan and about 20 mg of quinidine is administered per day. 
     
     
         14 . The method of  claim 1 , wherein about 40 mg of dextromethorphan and about 20 mg of quinidine is administered per day. 
     
     
         15 . The method of  claim 1 , wherein about 60 mg of dextromethorphan hydrobromide and about 20 mg of quinidine sulfate is administered per day. 
     
     
         16 . The method of  claim 1 , wherein about 40 mg of dextromethorphan hydrobromide and about 20 mg of quinidine sulfate is administered per day. 
     
     
         17 . A method of treating pain associated with diabetic neuropathy, the method comprising administering to a patient in need thereof dextromethorphan in combination with quinidine, wherein the amount of dextromethorphan administered is 120 mg/day and wherein the amount of quinidine administered is 120 mg/day.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.